Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153887 | 0.90 | MEN1 (0.50) | SIGMAR1MEN1KMT2ABCHEACHE | |
| SCHEMBL3136004 | 0.90 | SIGMAR1 (0.48) | SIGMAR1MEN1KMT2ABCHEACHE | |
| SCHEMBL3145609 | 0.88 | MEN1 (0.54) | SIGMAR1MEN1KMT2ABCHEACHE | |
| Trifluoroacetic Acid SCHEMBL3137027 | 0.87 | MEN1 (0.47) | SIGMAR1MEN1KMT2ABCHEACHE | |
| Trifluoroacetic Acid SCHEMBL3150246 | 0.86 | SIGMAR1 (0.45) | SIGMAR1MEN1KMT2ABCHEACHE | |
| Trifluoroacetic Acid SCHEMBL3136128 | 0.84 | NPSR1 (0.49) | SIGMAR1MEN1KMT2ABCHEACHE | |
| SCHEMBL4714274 | 0.83 | ABCB11 (0.54) | SIGMAR1MEN1KMT2ABCHEACHE | |
| SCHEMBL3135724 | 0.82 | ABCB11 (0.72) | SIGMAR1MEN1KMT2ABCHEACHE | |
| SCHEMBL3136342 | 0.82 | ABCB11 (0.51) | SIGMAR1MEN1KMT2ABCHEACHE | |
| SCHEMBL3145163 | 0.82 | MEN1 (0.55) | SIGMAR1MEN1KMT2ABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | claimed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | claimed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | claimed |
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | SIGMAR1 1722/4885MEN1 4733/4885KMT2A 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.